机构地区:[1]南京中医药大学附属中西医结合医院内分泌科,210028
出 处:《中华糖尿病杂志》2017年第11期714-719,共6页CHINESE JOURNAL OF DIABETES MELLITUS
摘 要:目的探讨天芪降糖胶囊对糖尿病肾病(DKD)大鼠模型肾功能的影响及其机制。方法将60只体重为180~200g8周龄雄性sD大鼠按照随机数字表法分为空白对照组、DKD模型组、厄贝沙坦组以及天芪降糖胶囊低、中和高剂量组共6组,每组10只,采用链脲佐菌素(35mg/kg)单次腹腔注射法造成DKD大鼠模型,成模后以厄贝沙坦[20mg/(kg·d)]或天芪降糖胶囊水溶液[O.32、0.64、1.28g/(kg·d)]灌胃。12周后称体重,测血糖、血脂,收集大鼠24h尿液,测尿微量白蛋白值,收集血清检测转化生长因子B1(TGF.p1)含量。一侧肾脏做病理形态学检查,另一侧肾脏匀浆后测超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH.Px)活性,以方差分析(ANOVA)、最小显著性差异法(LSD法)或多重比较校正法(Bonferroni法)进行统计学分析。结果12周后,天芪降糖胶囊高剂量组空腹血糖【(23.8+3.5)比(29.4±3.3)mmol/L]、总胆固醇【(1.67+0.32)比(2.40±0.19)mmol/L]、甘油三酯[(1.62±0.25)比(2.76±0.64)mmol/L]、24h尿微量白蛋白含量【(1411±156)比(2018±259)μg/24h】、血清TGF-p1含量[(333±46)kL(650±64)μg/ml]均低于模型组,肾组织SOD[(402±22)比(223±32)U/m1]、GSH-Px活性『(1633±37)比(1181±53)U/m1]均高于模型组(均P〈0.05),与厄贝沙坦组相近甚至更优。肾脏组织学观察显示,与模型组相比,天芪降糖胶囊高剂量组。肾小球形态正常,基底膜无增厚,系膜细胞数量无增多,系膜区基质明显减少,肾小管上皮细胞水肿减轻。结论高剂量天芪降糖胶囊可降低DKD大鼠血糖、血脂、蛋白尿,改善肾脏纤维化,延缓DKD的发展进程。其作用机制可能与增强肾脏抗氧化应激和抗纤维化功能有关。Objective To explore the protective effect of Tianqi Jiangtang capsule on kidney in rats with diabetic kidney disease (DKD) and its mechanisms. Methods A total of 60 eight-weeks old male SD rats were randomly and equally divided into 6 groups: control group (normal group), DKD model group (DKD group), irbesartan group [20 mg/(kg, d)], low-dose Tianqi group [0.32 g/(kg" d)], mid-close Tianqi group [0.64 g/(kg- d)] and high-dose Tianqi group [1.28 g/(kg, d)]. DKD rat model was established by single-dose intraperitoneal injection of streptozotocin (35 mg/kg). The experimental group rats were fed with irbesartan and different doses of Tianqi Jiangtang capsule, the model group rats with normal saline. Weight, plasma glucose and lipids, 24-hour urine and serum sample was collected to detect urinary microalbumin and transforming growth factor-β1 (TGF-β1)after twelve weeks. Kidney tissues of all the rats were collected. One kidney was used for morphological examination, and the other one was homogenized for measurement of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities. Variance analysis(ANOVA), least-significant difference(LSD) and multiple comparison correction (Bonferroni correction) were used for statistical analysis. Results Compared with DKD group, the level of fasting plasma glucose [(23.8~3.5) vs (29.4±3.3) mmol/L], total cholesterol [(1.67±0.32) vs (2.40±0.19) mmol/L] and triglyceride [(1.62±0.25) vs (2.76±0.64) mmol/L], 24 h urine mieroalbumin[(1 411 ± 156) vs (2 018 ± 259) Ixg/24 h] and serum TGF-I31 level [(333~46) vs (650+64) μg/ml] were decreased in high dose of Tianqi group (all P〈0.05). Level of SOD [(402 ± 22) vs (223 ± 32) U/ml] and GSH-Px activities [(1 633±37) vs (1 181 ± 53) U/ml] were significantly increased (all P〈0.05), similar to the irbesartan group, even better. Compared with DKD group, there was no thickening of glomerular bas
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...